Medicare Enrolled
Dr. George Hajjar, MD
Hematology & Oncology · Santa Clarita, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hajjar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hajjar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hajjar
Dr. George Hajjar is a hematology & oncology specialist in Santa Clarita, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Hajjar performed 39,506 Medicare services across 1,112 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hajjar received a total of $21,291 from 36 pharmaceutical and/or device companies across 147 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hajjar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 17% volume in CA
$21,291 industry payments
Medicare Practice Summary
Medicare Utilization ↗39,506
Medicare services
Top 17% in CA for hematology & oncology
1,112
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,975 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 20,760 | $23 | $106 |
| Pembrolizumab injection (Keytruda) | 4,800 | $43 | $194 |
| Anti-nausea injection (aprepitant) | 3,380 | $1 | $6 |
| Denosumab injection (Prolia/Xgeva) | 3,000 | $18 | $82 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
2,060 | $36 | $159 |
| Injection, leucovorin calcium, per 50 mg | 828 | $3 | $14 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
826 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 600 | $0 | $0 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
492 | $2 | $8 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
396 | $88 | $392 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
379 | $101 | $481 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
286 | $120 | $606 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
189 | $65 | $341 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
188 | $14 | $93 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
188 | $65 | $287 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
126 | $2 | $9 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
104 | $25 | $134 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
93 | $12 | $81 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
70 | $59 | $295 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
63 | $99 | $428 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
60 | $156 | $448 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
58 | $59 | $269 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
58 | $18 | $88 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
57 | $18 | $84 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
56 | $25 | $109 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
56 | $1 | $4 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
50 | $26 | $147 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
46 | $144 | $631 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
38 | $31 | $134 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
26 | $17 | $81 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
25 | $29 | $220 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
25 | $106 | $471 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
24 | $154 | $672 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
23 | $132 | $623 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
23 | $1 | $24 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 19 | $14 | $62 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
17 | $22 | $103 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
17 | $47 | $341 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.7% high complexity
90.6% medium
2.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$21,291
Total received (2018-2024)
Avg $3,042/year across 7 years
Top 20% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
147
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$13,429 (63.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,458 (25.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,404 (11.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,287
2023
$149
2022
$9,517
2021
$31
2020
$5,504
2019
$2,087
2018
$717
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$3,058
SOBI, INC
$200
PFIZER INC.
$29
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$9,641
Athenex Pharmaceutical Division, LLC
$3,850
AstraZeneca Pharmaceuticals LP
$3,226
Incyte Corporation
$2,000
PFIZER INC.
$314
SOBI, INC
$200
Pharmacyclics LLC, An AbbVie Company
$193
E.R. Squibb & Sons, L.L.C.
$190
Merck Sharp & Dohme Corporation
$172
Genentech USA, Inc.
$170
Merck Sharp & Dohme LLC
$125
Seattle Genetics, Inc.
$125
Medtronic USA, Inc.
$113
IntrinsiQ Specialty Solutions, Inc.
$100
Cardinal Health 110 LLC
$100
Janssen Biotech, Inc.
$94
Takeda Pharmaceuticals U.S.A., Inc.
$79
Clovis Oncology, Inc.
$73
GENZYME CORPORATION
$70
Puma Biotechnology, Inc.
$57
Bayer HealthCare Pharmaceuticals Inc.
$46
EISAI INC.
$45
Gilead Sciences, Inc.
$34
Seagen Inc.
$34
Novartis Pharmaceuticals Corporation
$34
Regeneron Healthcare Solutions, Inc.
$26
EMD Serono, Inc.
$23
Astellas Pharma US Inc
$22
Kyowa Kirin, Inc.
$20
Heron Therapeutics, Inc.
$19
Eisai Inc.
$18
EUSA Pharma (US) LLC
$16
Avadel Specialty Pharmaceuticals, LLC
$16
MEDIVATION FIELD SOLUTIONS LLC
$16
Lilly USA, LLC
$15
Myriad Genetic Laboratories, Inc.
$15
Top 3 companies account for 78.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Alecensa · Aliqopa · Aranesp · Avastin · BAVENCIO · BOSULIF · Bavencio · CALQUENCE · CINVANTI · CYRAMZA · DARZALEX · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · Erleada · FASENRA · IBRANCE · IMFINZI · INLYTA · Imbruvica · KEYTRUDA · KYPHON Balloon Kyphoplasty · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · MVASI · NINLARO · Nerlynx · Neulasta · Noctiva · OPDIVO · Oral Paclitaxel · Perjeta · Rubraca · SANCUSO · SANDOSTATIN · SUTENT · Sylvant · TALZENNA · TECENTRIQ · Truqap · VONJO · XALKORI · XGEVA · XTANDI · Xofigo · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (63%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Hematology & oncology specialists within 10 mi
133
Per 100K population
1.4
County median income
$87,760
Nearest hospital
HENRY MAYO NEWHALL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Hajjar is a mixed practice specialist, with above-average Medicare volume (top 17% in CA), with speaking/promotional industry engagement in the top 20% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Hajjar experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Hajjar performed 20,760 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hajjar receive payments from pharmaceutical companies?
Yes. Dr. Hajjar received a total of $21,291 from 36 companies across 147 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hajjar's costs compare to other hematology & oncology specialists in Santa Clarita?
Dr. Hajjar's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hajjar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Santa Clarita
Browse hematology & oncology specialists in Santa Clarita ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Athenex Pharmaceutical Division, LLC Payments to Doctors
See all physicians who received payments from Athenex Pharmaceutical Division, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology